Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer.

ABSTRACT:

Introduction

Patients with BRAF V600E-mutated/microsatellite stable (MSS) metastatic colorectal cancer (mCRC) are associated with a poor prognosis. Backline treatment has minimal efficacy. Multi-target inhibitors of the RAS-RAF-MEK signaling pathway combined with PD-1 monoclonal antibody may be a promising strategy for BRAF V600E-mutated mCRC.

Methods

This prospective phase I trial enrolled patients to explore tolerability and safety of the VCC regimen in previously treated patients with BRAF V600E-mutated/MSS mCRC. Enrolled patients treated with VCC therapy every 2 weeks (cetuximab 500mg/m²; camrelizumab 200 mg; vemurafenib 960 mg orally once daily). Adverse events and efficacy were monitored and recorded throughout the administration and follow-up period.

Res

SUBMITTER: Wei GX 

PROVIDER: S-EPMC12613881 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature